ReoPro market seen doubling by 2030 as cardiac care demand rises
The ReoPro (abciximab) market is forecast to grow from $1.31 million in 2025 to $2.11 million by 2030, driven by more PCI procedures, an aging population and higher cardiovascular disease rates. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.
Why it matters: - ReoPro remains a niche but important therapy in emergency heart care and high-risk cardiac procedures. - The forecast points to steady demand for antiplatelet support as hospitals expand catheterization labs and interventional cardiology services. - Growing cardiovascular disease rates and an older patient population are expected to keep procedure volumes elevated.
What happened: - The Business Research Company released its ReoPro (abciximab) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the ReoPro market will rise from $1.31 million in 2025 to $1.44 million in 2026. - The report projects the market will reach $2.11 million by 2030. - The report says 2025 was the year North America held the largest market share. - The report says Asia-Pacific is expected to be the fastest-growing region through the forecast period.
The details: - ReoPro is a monoclonal antibody that targets the glycoprotein IIb/IIIa receptor on platelets. - The drug is used during percutaneous coronary interventions to help prevent blood clot formation. - The report links recent market growth to acute coronary syndromes, early PCI adoption, hospital use of antiplatelet therapies, guideline support for high-risk patients and established clinical efficacy. - The report cites ongoing demand in complex PCI cases, better catheterization lab infrastructure, broader interventional cardiology services, rising cardiovascular disease and continued clinical protocol optimization as future growth drivers. - The report highlights sustained use in high-risk cardiac interventions, more attention to procedural anticoagulation safety, broader emergency cardiac care protocols, better PCI outcomes and more refined patient selection for glycoprotein IIb/IIIa inhibitors. - The report says healthcare infrastructure expansion supports ReoPro use by enabling more catheterization labs and higher PCI volumes. - As of May 2023, the United States had 6,129 hospitals, up 0.591% from 6,093 a year earlier, according to the American Health Care Association. - The report says the aging population is helping demand because older patients are more likely to need PCI and face higher cardiovascular risk. - Data from the Administration for Community Living showed 17.3% of the U.S. population was age 65 or older in 2022, with that share projected to reach 22% by 2040. - The report says rising cardiovascular disease prevalence is also expanding demand for the drug. - The British Heart Foundation said more than 7.6 million people in the UK lived with cardiovascular disease in September 2025, with the total expected to rise by about 1 million by 2030 and about 2 million by 2040. - The report covers Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America and Asia-Pacific. - The company said the 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies and future trends, and updated graphics and tables. - The company also offered a free sample and the full report through its website, with links to the sample request and the full report.
Between the lines: - The forecast suggests ReoPro’s market growth is tied more to procedure volume and patient mix than to broad mass-market pharmaceutical demand. - North America’s lead likely reflects mature cardiac care infrastructure, while Asia-Pacific’s growth outlook points to expanding access and rising cardiovascular burden. - The emphasis on procedural safety and patient selection suggests the market is becoming more specialized, not simply larger.
What's next: - Demand is likely to track the pace of PCI growth, especially in complex and emergency cases. - Further hospital and catheterization lab expansion could support additional uptake. - Market growth will likely depend on how quickly health systems in fast-growing regions build interventional cardiology capacity. - The report’s 2030 forecast implies continued but measured expansion rather than a sharp spike.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
News From Europe!
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.